Geode Capital Management’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-60,988
| Closed | -$453K | – | 4521 |
|
|
2026
Q1 | $453K | Sell |
60,988
-7,179
| -11% | -$46.7K | ﹤0.01% | 3622 |
|
|
2025
Q4 | $429K | Buy |
68,167
+2,665
| +4% | +$15.5K | ﹤0.01% | 3645 |
|
|
2025
Q3 | $256K | Buy |
65,502
+383
| +0.6% | +$1.57K | ﹤0.01% | 3850 |
|
|
2025
Q2 | $298K | Sell |
65,119
-2,445
| -4% | -$10.5K | ﹤0.01% | 3735 |
|
|
2025
Q1 | $330K | Buy |
67,564
+994
| +1% | +$6.03K | ﹤0.01% | 3688 |
|
|
2024
Q4 | $447K | Buy |
66,570
+3,879
| +6% | +$28.9K | ﹤0.01% | 3634 |
|
|
2024
Q3 | $485K | Buy |
62,691
+8,168
| +15% | +$49.3K | ﹤0.01% | 3587 |
|
|
2024
Q2 | $327K | Sell |
54,523
-82,846
| -60% | -$630K | ﹤0.01% | 3731 |
|
|
2024
Q1 | $1.24M | Buy |
137,369
+1,904
| +1% | +$17.3K | ﹤0.01% | 3282 |
|
|
2023
Q4 | $1.28M | Buy |
135,465
+6,203
| +5% | +$54.5K | ﹤0.01% | 3248 |
|
|
2023
Q3 | $1.54M | Buy |
129,262
+5,586
| +5% | +$99K | ﹤0.01% | 3169 |
|
|
2023
Q2 | $3.03M | Buy |
123,676
+20,180
| +19% | +$525K | ﹤0.01% | 2963 |
|
|
2023
Q1 | $3.24M | Buy |
103,496
+5,807
| +6% | +$336K | ﹤0.01% | 2821 |
|
|
2022
Q4 | $6.88M | Buy |
97,689
+3,599
| +4% | +$267K | ﹤0.01% | 2483 |
|
|
2022
Q3 | $8.1M | Buy |
94,090
+16,479
| +21% | +$1.6M | ﹤0.01% | 2387 |
|
|
2022
Q2 | $6.42M | Buy |
77,611
+10,188
| +15% | +$899K | ﹤0.01% | 2559 |
|
|
2022
Q1 | $11.2M | Buy |
67,423
+5,616
| +9% | +$806K | ﹤0.01% | 2278 |
|
|
2021
Q4 | $10.3M | Buy |
61,807
+1,339
| +2% | +$151K | ﹤0.01% | 2422 |
|
|
2021
Q3 | $5.22M | Buy |
60,468
+3,122
| +5% | +$207K | ﹤0.01% | 2890 |
|
|
2021
Q2 | $3.11M | Buy |
57,346
+6,113
| +12% | +$347K | ﹤0.01% | 3130 |
|
|
2021
Q1 | $3.05M | Buy |
51,233
+4,182
| +9% | +$244K | ﹤0.01% | 3039 |
|
|
2020
Q4 | $2.46M | Buy |
47,051
+4,145
| +10% | +$231K | ﹤0.01% | 2970 |
|
|
2020
Q3 | $2.08M | Buy |
42,906
+1,006
| +2% | +$48.1K | ﹤0.01% | 2860 |
|
|
2020
Q2 | $2.17M | Sell |
41,900
-352
| -0.8% | -$17.8K | ﹤0.01% | 2794 |
|
|
2020
Q1 | $1.84M | Buy |
42,252
+29,307
| +226% | +$1.19M | ﹤0.01% | 2713 |
|
|
2019
Q4 | $519K | Buy |
12,945
+386
| +3% | +$11.9K | ﹤0.01% | 3488 |
|
|
2019
Q3 | $411K | Buy |
12,559
+467
| +4% | +$22.5K | ﹤0.01% | 3538 |
|
|
2019
Q2 | $932K | Buy |
12,092
+2,714
| +29% | +$422K | ﹤0.01% | 3259 |
|
|
2019
Q1 | $1.66M | Buy |
9,378
+3,573
| +62% | +$704K | ﹤0.01% | 2959 |
|
|
2018
Q4 | $1.37M | Buy |
5,805
+3,244
| +127% | +$793K | ﹤0.01% | 2968 |
|
|
2018
Q3 | $548K | Buy |
+2,561
| New | +$447K | ﹤0.01% | 3428 |
|
Geode Capital Management's KZR Position: Q2 2026 in Review
Geode Capital Management sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 60,988 shares — an estimated $453K sold.
Geode Capital Management first reported a position in KZR in Q3 2018 and held it in 31 quarters. The position peaked at $11.2M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Geode Capital Management reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Geode Capital Management sold 60,988 Kezar Life Sciences shares in Q2 2026, an estimated $453K.
- Geode Capital Management first reported a position in Kezar Life Sciences in Q3 2018 and held it in 31 quarters.
- Geode Capital Management's Kezar Life Sciences position peaked at $11.2M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.